Added: Feb 22, 2012
From: CHSRF
Duration: 56:16
Because generics offer the same quality advantages as their branded counterparts, generic drug manufacturers compete for market share by offering low prices. The Ontario Drug Benefit (ODB) program currently has a fixed rate which does not necessarily align with the cost of producing the drugs. In this session of CHSRF on Call, Aidan Hollis, Professor, Dept of Economics, University of Calgary and Matthew Brougham, Vice-President, Products and Services, Canadian Agency for Drugs and Technology in Health, explore two options for generic drug pricing: ■ the implementation of sliding scale, and ■ using tendering systems to reward producers while better aligning payment with production costs. Join the discussion.
Channel: Nonprofit
Tags: pricing chsrf generic drug spending healthcare canada chsrf on call
Views: 56 Comments: 0












